We are an international and independent pharmaceutical group with a human scale, governed by a Foundation. Our unique model is our pride but, above all, it enables us to fully serve our vocation: “Committed to therapeutic progress for the benefit of patients”.
A global leader in cardiology today, we have chosen to become a focused and innovative player in oncology by 2030, by targeting hard-to-treat cancers and dedicating more than 70% of our R&D budget to them. This is a challenge we are pursuing alongside the development of our generic business to ensure access to quality healthcare for all, at a lower cost.
Who are we? 22,000 passionate employees of more than 50 nationalities, driven by an entrepreneurial spirit. Every day, we move forward with and for patients, with and for our teams, driven by the desire to care, to dare, to develop, and to commit ourselves to being useful to those who need it.
Come and experience our commitment, and help us bring it to life #MovedByYou
As a Clinical Pathology and Histopathology support Technician, you will interact on a daily basis with colleagues from Non-Clinical Safety and the Animal Science divisions. This mixed role involves responsibility for analyzing biological samples and developing new assay methods, while providing essential technical support to histopathology activities (tissue processing, slides preparation and Histology technologies development).
We are committed to equal opportunity and the development of talent in all its diversity. We value experience as much as the desire to commit daily to being useful to therapeutic progress for the benefit of patients. If you recognize yourself in this offer and these few lines, take this opportunity to meet us.

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle.
As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D.
Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion.
--
To report a suspected adverse event with a Servier drug, please visit servier.com